Y’all know what I love? Open access science, that’s what. And that’s why this week’s good news about cell therapy comes from an article that’s freely available to every single one of you, right here on the regular old internet. This study actually came out about a year ago, but I think it deserves a little more attention than it’s received thus far. Here’s why: this study executed a head to head comparison of hyaluronic acid (HA) injections (aka viscosupplementation) and platelet rich plasma (PRP), which is frequently a topic of conversation with doctor and patients. The authors concluded that PRP achieved longer lasting results in all patients and was more effective in reducing pain and disability (as measure by a quality of life scale) in patients with less severe arthritis. – Read More –
If you have been following this blog and keeping up with the fascinating world of regenerative medicine, you know that all adult stem cells are not the same. There are different progenitor cell types like Hematopoietic stem cells (HSCs) and Mesenchymal stem cells (MSCs) that are derived from bone marrow. HSCs give rise to all the cells in the blood, including immune cells like B cells and T cells, through the process of hematopoiesis and here is an excellent review on MSCs and the therapeutic benefits they provide. – Read More –
You heard it here first folks, unless you read the same Nature Communications article as me, in which case you heard it there first. Either way: 3D printed organs are a reality! For mice right now, but scale-wise it’s not that far from humans. This first foray into functioning 3D printed replacements involves a number of unique situations though, so don’t go ruining your liver just yet. – Read More –
Alright y’all, let’s get real. Most of us are pretty comfortable with the idea that mesenchymal stem cells (MSCs) can become cartilage, bone, fat, and connective tissue cells (among other awesome properties). Thousands upon thousands of patients’ worth of studies have been published using bone marrow-derived MSCs for everything from avascular necrosis to peripheral artery disease, many of which constitute the most effective, ground-breaking treatments for their respective pathologies. But it’s still not enough, right? If you’re at all like me, you hope to see stem cell technology evolve to the point of keeping spare parts in jars, so we can live in a future where organ donors are an archaic thing of the past. That is just not happening when MSCs can only become a select few cell types. Brace yourselves though: scientists just found a way to change that.
In my previous blog, I talked about the different routes used to deliver stem cells focusing on systemic delivery. Regardless of the delivery route chosen, labeling and tracking stem cells in vivo (within the organism) helps in determining their survival rate, where they migrated to and how many cells were retained in the area of interest. This provides us with insights into the therapeutic benefits of regenerative treatments. In this blog, I will discuss the current techniques being used to label stem cells. – Read More –